Genetic screening has revealed hundreds of individuals with Jewish heritage to have a higher risk of developing cancer. The NHS in England recently launched a genetic testing programme specifically for individuals of Jewish descent due to their increased vulnerability to certain types of cancer. Fresh data from the programme indicates that 235 people have been identified as having an elevated cancer risk. These individuals will receive additional support, including preventive treatments and enhanced screening to detect early signs of cancer.
The screening programme focuses on detecting mutations in the BRCA genes, which can significantly raise a person’s cancer risk. While everyone carries the BRCA1 and BRCA2 genes, alterations in these genes can heighten the risk of specific cancers such as breast, ovarian, prostate, and pancreatic cancers. Ethnicity plays a role in the likelihood of carrying these gene mutations, with four in every 10 individuals of Ashkenazi Jewish ancestry found to have the gene change in BRCA1 and BRCA2, and one in 140 Sephardi Jews having a faulty BRCA gene.
As part of the screening programme, individuals in England over 18 years old with Jewish ancestry are offered a simple saliva test. The saliva samples are self-collected at home and sent to a lab for analysis. In the first year of the NHS Jewish BRCA Testing Programme, there has been a significant uptake, with 25,000 free saliva test kits requested and delivered. Out of approximately 11,000 tests processed to date, 235 individuals (2.1%) have tested positive for a BRCA gene mutation. Those identified as carrying altered BRCA genes receive early access to cancer detection services such as mammograms or MRI scans, may be offered preventive measures, and are counselled on lifestyle changes.
Professor Peter Johnson, NHS England’s national clinical director for cancer, emphasized the importance of early identification and support for individuals with an increased cancer risk. The collaborative effort between NHS England, Jnetics, and Chai Cancer Care has been well-received, with a focus on raising awareness and providing the opportunity for individuals to make informed decisions regarding their health. Health Minister Andrew Gwynne highlighted the success of the programme in providing reassurance and education on cancer risks while enabling individuals to make informed choices about their health.
Overall, the genetic testing programme for individuals with Jewish heritage in England has shown promising results in identifying those at a higher risk of cancer and providing them with the necessary support and resources for early detection and intervention. The initiative underlines the importance of proactive screening and genetic testing in managing the risk of hereditary cancers within specific communities.